Propanc Biopharma, Inc. financial data

Symbol
PPCB on Nasdaq
Location
Camberwell, Victoria, Australia
Fiscal year end
30 June
Latest financial report
10-Q - Q4 2025 - 17 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 202% % 40735%
Debt-to-equity 31% %
Return On Equity -465% % -1197%
Return On Assets -351% % 87%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,859,280 shares 37%
Common Stock, Shares, Outstanding 13,449,688 shares
Entity Public Float $47,895 USD -89%
Common Stock, Value, Issued $13,450 USD
Weighted Average Number of Shares Outstanding, Basic 13,360,358 shares 100000%
Weighted Average Number of Shares Outstanding, Diluted 13,360,358 shares 100000%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $187,781 USD -20%
General and Administrative Expense $64,880,245 USD 6982%
Operating Income (Loss) $65,102,257 USD -5394%
Nonoperating Income (Expense) $965,682 USD -99%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $66,067,939 USD -3855%
Income Tax Expense (Benefit) $275 USD 84%
Net Income (Loss) Attributable to Parent $66,067,939 USD -3857%
Earnings Per Share, Basic 52.66 USD/shares 99%
Earnings Per Share, Diluted 52.66 USD/shares -26%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current $1,400 USD
Assets, Current $7,706,924 USD 42754%
Property, Plant and Equipment, Net $4,397 USD
Operating Lease, Right-of-Use Asset $50,901 USD
Assets $15,111,532 USD 19142%
Accounts Payable, Current $957,483 USD -22%
Employee-related Liabilities, Current $703,190 USD 15%
Liabilities, Current $3,624,018 USD -13%
Operating Lease, Liability, Noncurrent $35,249 USD
Liabilities $3,659,267 USD -14%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,328,115 USD -11%
Retained Earnings (Accumulated Deficit) $134,482,898 USD -99%
Stockholders' Equity Attributable to Parent $10,452,265 USD
Liabilities and Equity $15,111,532 USD 19142%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,939,067 USD -723%
Net Cash Provided by (Used in) Financing Activities $2,526,772 USD 1071%
Net Cash Provided by (Used in) Investing Activities $2,491 USD
Common Stock, Shares Authorized 10,000,000,000 shares 0%
Common Stock, Shares, Issued 13,449,688 shares
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $590,649 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $115,691 USD 4339%
Deferred Tax Assets, Valuation Allowance $23,846,119 USD 108%
Deferred Tax Assets, Gross $28,447,509 USD 136%
Operating Lease, Liability $62,126 USD
Depreciation $229 USD
Payments to Acquire Property, Plant, and Equipment $2,491 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $67,163,938 USD -4604%
Lessee, Operating Lease, Liability, to be Paid $56,853 USD 679%
Property, Plant and Equipment, Gross $30,203 USD 28%
Operating Lease, Liability, Current $21,604 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $24,256 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $27,952 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $21,734 USD
Deferred Tax Assets, Operating Loss Carryforwards $25,483,996 USD 181%
Preferred Stock, Shares Authorized 1,500,005 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $143,640,067 USD 132%
Deferred Tax Assets, Net of Valuation Allowance $23,846,119 USD 108%
Share-based Payment Arrangement, Expense $1,789,262 USD
Interest Expense $690,079 USD 30%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%